Back to all Programs

Past Event

Related Materials

Past Event

1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025

Promo Video | LAAI 2025

Long-Acting Anti-Infectives: Where Do We Stand? - Charles Flexner

Regulatory Considerations for Long-Acting Anti-Infectives: Challenges and Opportunities - Kellie Schoolar Reynolds

Long-Acting Antiretroviral Monoclonal Antibodies: Revolutionizing HIV Prevention - Huub Gelderblom

Getting It Right This Time: The Impact of PEPFAR Stop Work Orders on Injectable PrEP and Implications for LEN Rollout - Stacey Hannah

Pharmacokinetic Considerations of Long-Acting Anti-Infective Administration During Pregnancy - Robert Bies

The Long-Acting Anti-Infective Agents for Children and Adolescents: Are We Nearly There Yet? - Natella Rakhmanina

Clinical Development of Long-Acting Formulations for Treatment and Prevention of Tuberculosis - Kimberly Scarsi

Long-Acting Anti-Infectives in Resource-Limited Settings - François Venter

Long-Acting Therapies for Emerging Infections: Insights from COVID-19 - Daniel Kuritzkes

Monoclonal Antibodies for RSV Prevention - Sarah Hak

Abstract #1 Proof-of-Concept Study of Oral VH4004280, a New HIV-1 Capsid Inhibitor – Paul Benn

Abstract LB #1 What Do Early Adopters of Long-Acting Injectable Cabotegravir-Rilpivirine Think About It? - Katerina Christopoulos

Abstract #2 Utilization and Effectiveness of Cabotegravir + Rilpivirine in People with HIV (PWH) with Viremia at Treatment Initiation - Richard A. Elion

Abstract #3 Novel Ultra-Long-Acting Injectable Formulations of Bictegravir - Xiaohong Qi

Abstract #4 Facilitators and Barriers to Long-Acting Injectable Antiretroviral Therapy Uptake among Youth Living with HIV in Cape Town, South Africa: A COM-B Analysis - Sheree Schwartz

Abstract #5 Cabotegravir and Rilpivirine in Pregnancy: A Multi-Center Study Evaluating HIV Viral Suppression, Perinatal and Neonatal Outcomes - William Short

Abstract LB #2 Twice-Yearly Lenacapavir PrEP in Cisgender Gay Men, Transgender Women and Men, and Gender-Diverse People (PURPOSE 2) - Meredith Clement

Abstract #6 Development of Long-Acting Telacebec (Q203) for Treatment of M. tuberculosis, M. ulcerans and M. leprae - Martina Kovarova

Abstract #7 First in Human Dose Predictions Scaled from Preclinical Pharmacokinetics for LAI Rifabutin - Doaa Ahmed Mohamed

Abstract LB #3 Clinical Development of Long-Acting Formulations for TB Treatment and Prevention: Insights from the Bedaquiline Long-Acting TMC207TBC1006 Phase 1 Trial – Vivan Cox

Abstract #8 VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study - Rulan Griesel

Viral Hepatitis and Liver Disease

Abstract #9 LAPaL: Your Free Digital Compass in the Evolving Long-Acting Therapeutics Landscape - Lobna Gaayeb

Viral Hepatitis and Liver Disease

Abstract LB #4 Global Perspectives of People Living with Hepatitis B on Long-Acting Antivirals: Survey Results - Yasmin Ibrahim

Long-Acting Injectable Formulation of Ivermectin as a New Vector Control Tool to Reduce Malaria Transmission - Quiterie Savary de Beauregard

Pharmacological Considerations of Routes of Administration for Long-Acting Injectable Products - Simone Perazzolo